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BLETTER TO THE EDITOR
uman Mesenchymal Stem Cells and Cyclosporin A
xert a Synergistic Suppressive Effect on
n Vitro Activation of Alloantigen-Specific
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lExperimental evidence and preliminary clinical
tudies have demonstrated that in vitro expanded hu-
an mesenchymal stem cells (MSCs) display an im-
ortant immune-modulatory function that can be rel-
vant in the setting of allogeneic hematopoietic stem
ell transplantation [1-4]. However, all these studies
ave investigated the effect played by MSCs without
onsidering the interaction with immunosuppressive
rugs, such as calcineurin inhibitors, which are largely
sed for the prevention of graft-versus-host disease
GVHD). Some of the immune-modulatory effects of
uman MSCs are dose dependent. In particular, at a
igh ratio with respect to the effector cells, MSCs
trongly inhibit in vitro activation of alloantigen-spe-
iﬁc cytotoxic lymphocytes, whereas at a low ratio they
ay either decrease or increase alloantigen-speciﬁc cell-
ediated cytotoxic activity [5,6]. Because alloantigen-
peciﬁc cytotoxic T lymphocytes play a crucial role in the
ffector phase of GVHD, the potential ability of low
oses of human MSCs to enhance alloantigen-speciﬁc
ell-mediated cytolytic activity in vitro seems apparently
o contrast with the documented capacity of human
SCs to control severe acute GVHD in vivo [1-3].
In view of these considerations, we have reasoned
hat the in vivo immunosuppressive effect of human
SCs in the setting of allogeneic hematopoietic stem
ell transplantation might be inﬂuenced by the phar-
acologic treatment used to prevent or cure GVHD.
o test this hypothesis, we evaluated in mixed lym-
hocyte culture (MLC) whether cyclosporin A (CsA)
an exert a synergistic cooperation with humanMSCs in
ownregulating alloantigen-speciﬁc cytotoxic activity.
o this purpose, primary and secondary MLCs were
erformed as previously described [6] in the presence or
bsence of MSCs, CsA (50 ng/mL), or both. MSCs,
ither third party or autologous to the MLC-responder
eripheral blood mononuclear cells (R), were added at
he relatively low R/MSC ratio of 10:1, which, in previ-
us experiments [6], was shown to be able to either
nhance or decrease alloantigen-speciﬁc cell-mediated
ytotoxic activity. The concentration of CsA was cho- p
B & M Ten in view of the results of several preliminary exper-
ments, which showed that the addition of 50 ng/mL
f the reagent to MLCs, in the absence of MSCs,
ould variably modulate alloantigen-speciﬁc cell-me-
iated cytotoxic activity, but it was unable to completely
brogate alloantigen-speciﬁc, cell-mediated cytotoxic ac-
ivity in vitro. On the contrary, CsA concentrations of
00, 200, or 400 ng/mL or MSCs at an R/MSC ratio of
:1 were able alone to strongly decrease alloantigen-
peciﬁc cell-mediated cytotoxic activity, thus prevent-
ng the possibility of documenting any synergistic ef-
ect promoted by the coaddition of the 2 reagents.
We found that, although the presence of MSCs
R/MSC ratio of 10:1) or CsA (50 ng/mL) alone could
igure 1. Effect of human MSCs, either of third-party origin
upper panel) or autologous (lower panel), with respect to MLC-
esponder cells and/or of CsA on alloantigen-speciﬁc cell-mediated
ytotoxic activity induced in MLCs. Speciﬁc lysis of allogeneic
arget cells was assessed after primary (I) MLC and secondary (II)
LC in the presence or absence (ctrl) of MSCs, CsA, or both.
lloantigen-speciﬁc cytotoxic activity was tested in a 5-hour chro-
ium 51 (51Cr)–release assay, as previously described [6]. Results
ere expressed as LU30/106 effector cells: 1 lytic unit (LU) is the
umber of effector cells required to induce 30% lysis of 51Cr-
abeled target cells (LU30). The 51Cr-labeled target cells included
hytohemagglutinin-activated MLC-stimulator cells.
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Letter to the Editor
1ither enhance or decrease MLC-induced alloantigen-
peciﬁc cell-mediated cytotoxic activity, the combina-
ion of the 2 reagents consistently exerts a synergistic
trong suppressive effect. Representative results of 2 out
f 4 separate experiments are reported in Figure 1.
In conclusion, our data demonstrate that an im-
unosuppressive drug that is currently used to pre-
ent or treat GVHD enhances the immunosuppres-
ive effect of human MSCs, thus providing a possible
nterpretation for the sometimes divergent results ob-
ained by studying in vivo or in vitro the immune-
odulatory effect of human MSCs.
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